First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors-Reference-Cited by-同舟云学术

First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors

Published:2021-02-25 Issue:4 Volume:112 Page:1514-1523
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Kondo Shunsuke¹^ORCID,Shimizu Toshio¹,Koyama Takafumi¹^ORCID,Sato Jun¹^ORCID,Iwasa Satoru¹,Yonemori Kan¹^ORCID,Fujiwara Yutaka¹²^ORCID,Shimomura Akihiko³^ORCID,Kitano Shigehisa¹⁴,Tamura Kenji⁵⁶^ORCID,Yamamoto Noboru¹^ORCID

Affiliation:

1. Department of Experimental Therapeutics National Cancer Center Hospital Tokyo Japan

2. Department of Respiratory Medicine Mitsui Memorial Hospital Tokyo Japan

3. Department of Breast and Medical Oncology National Center for Global Health and Medicine Tokyo Japan

4. Division of Cancer Immunotherapy Development Cancer Institute Hospital of JFCR Tokyo Japan

5. Department of Breast and Medical Oncology National Cancer Center Hospital Tokyo Japan

6. Innovative Cancer Center Shimane University Hospital Izumo Japan

Funder

Taiho Pharmaceutical

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14765

Reference32 articles.

1. Cancer Vaccines: A Brief Overview

2. Peptide-based materials for cancer immunotherapy

3. An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy

4. Phase I Trial of a Personalized Peptide Vaccine for Patients Positive for Human Leukocyte Antigen–A24 With Recurrent or Progressive Glioblastoma Multiforme

5. Cancer immunotherapy: moving beyond current vaccines

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma;Molecular Cancer Therapeutics;2024-01-11

2. Evaluation of the efficacy and safety of TAS0313 in adults with recurrent glioblastoma;Cancer Immunology, Immunotherapy;2022-04-04

3. Personalized Cancer Vaccines Targeting Neoantigens;Handbook of Cancer and Immunology;2022

4. Therapeutic cancer vaccines revamping: technology advancements and pitfalls;Annals of Oncology;2021-12

5. Breast cancer vaccines for treatment and prevention;Breast Cancer Research and Treatment;2021-11-30